Valuation: Akeso, Inc.

Capitalization 111B 127B 16.25B 13.85B 12.81B 12.07B 22.48B 1,512B 22.94B 150B 58.82B 726B 61B 59.71B 2,587B P/E ratio 2025
-82.6x
P/E ratio 2026 * 450x
Enterprise value 108B 124B 15.81B 13.47B 12.47B 11.74B 21.86B 1,471B 22.31B 146B 57.22B 706B 59.34B 58.08B 2,516B EV / Sales 2025
29.2x
EV / Sales 2026 * 20.3x
Free-Float
74.46%
Yield 2025 *
-
Yield 2026 * -
1 day-0.65%
1 week-0.15%
Current month+5.45%
1 month+24.59%
3 months+13.85%
6 months+8.45%
Current year+21.50%
1 week 132.8
Extreme 132.8
142
1 month 108.9
Extreme 108.9
142
Current year 93.65
Extreme 93.65
142
1 year 73.1
Extreme 73.1
179
3 years 26.45
Extreme 26.45
179
5 years 11.5
Extreme 11.5
179
10 years 11.5
Extreme 11.5
179
Manager TitleAgeSince
Corporate Officer/Principal 50 16/11/2019
Corporate Officer/Principal 57 16/11/2019
Chief Tech/Sci/R&D Officer 58 16/11/2019
Director TitleAgeSince
Chairman 59 19/03/2012
Director/Board Member 58 16/11/2019
Director/Board Member 57 16/11/2019
Change 5d. change 1-year change 3-years change Capi.($)
-0.58%-0.15%+57.91%+194.64% 16.25B
-0.62%+4.50%+28.52%+93.93% 49.79B
+0.13%+6.34%+104.09%+28.22% 46.97B
-3.00%-4.69%+125.77%+831.47% 33.42B
+3.83%+4.74%-1.06%-24.09% 24.15B
-1.89%+0.23%+66.32%-34.52% 18.97B
+0.04%+2.00%+40.23%-34.61% 17.25B
+1.86%+1.50%-15.36%+1,169.03% 15.25B
-1.62%-0.41%+51.09% - 14.68B
-0.89%-4.99%+63.84%+115.13% 11.92B
Average -0.27%+0.90%+52.13%+259.91% 24.86B
Weighted average by Cap. -0.33%+2.05%+58.94%+232.16%

Financials

2025 2026 *
Net sales 3.29B 3.77B 481M 410M 380M 357M 666M 44.78B 679M 4.45B 1.74B 21.5B 1.81B 1.77B 76.61B 5.19B 5.95B 760M 647M 599M 564M 1.05B 70.69B 1.07B 7.03B 2.75B 33.94B 2.85B 2.79B 121B
Net income -271M -310M -39.64M -33.77M -31.25M -29.43M -54.81M -3.69B -55.93M -367M -143M -1.77B -149M -146M -6.31B 239M 274M 34.97M 29.79M 27.57M 25.96M 48.36M 3.25B 49.35M 323M 127M 1.56B 131M 128M 5.57B
Net Debt -3.03B -3.47B -443M -377M -349M -329M -613M -41.21B -625M -4.1B -1.6B -19.79B -1.66B -1.63B -70.51B -5.62B -6.45B -823M -701M -649M -611M -1.14B -76.54B -1.16B -7.61B -2.98B -36.75B -3.09B -3.02B -131B
Logo Akeso, Inc.
Akeso Inc is an investment holding company mainly engaged in the research and development, production and commercialization of biopharmaceutical products. The Company is committed to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwide. The Company's products mainly include cadonilimab (PD-1/CTLA-4), Ivonescimab (AK112, PD-1/VEGF), ANNIKO (penpulimab, PD-1), Ebronucimab (AK102, PCSK9) and ebdarokimab (AK101, IL-12/IL-23). The Company's products are principally used to treat tumors, autoimmune diseases, metabolic diseases, as well as neurodegenerative diseases. The Company principally conducts its businesses in Mainland China, the United States and other markets.
Employees
3,761
Date Price Change Volume
13/04/26 137.40 $ -0.58% 5,044,601
10/04/26 138.20 $ +1.99% 4,227,095
09/04/26 135.50 $ -1.45% 5,649,136
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
120.48CNY
Average target price
151.36CNY
Spread / Average Target
+25.62%

Quarterly revenue - Rate of surprise